179 related articles for article (PubMed ID: 31587492)
1. Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia.
Kizhakkedath P; John A; Al-Sawafi BK; Al-Gazali L; Ali BR
FEBS Open Bio; 2019 Nov; 9(11):1994-2005. PubMed ID: 31587492
[TBL] [Abstract][Full Text] [Related]
2. Familial hypercholesterolemia class II low-density lipoprotein receptor response to statin treatment.
Omer L; Hindi L; Militello G; Stivers KB; Tien KC; Boyd NL
Dis Model Mech; 2020 Apr; 13(4):. PubMed ID: 32005714
[TBL] [Abstract][Full Text] [Related]
3. A novel indel variant in LDLR responsible for familial hypercholesterolemia in a Chinese family.
Shu H; Chi J; Li J; Zhang W; Lv W; Wang J; Deng Y; Hou X; Wang Y
PLoS One; 2017; 12(12):e0189316. PubMed ID: 29228028
[TBL] [Abstract][Full Text] [Related]
4. Mutations affecting the transmembrane domain of the LDL receptor: impact of charged residues on the membrane insertion.
Strøm TB; Laerdahl JK; Leren TP
Hum Mol Genet; 2017 May; 26(9):1634-1642. PubMed ID: 28334946
[TBL] [Abstract][Full Text] [Related]
5. The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.
Susan-Resiga D; Girard E; Kiss RS; Essalmani R; Hamelin J; Asselin MC; Awan Z; Butkinaree C; Fleury A; Soldera A; Dory YL; Baass A; Seidah NG
J Biol Chem; 2017 Feb; 292(5):1573-1590. PubMed ID: 27998977
[TBL] [Abstract][Full Text] [Related]
6. Systematic prediction of familial hypercholesterolemia caused by low-density lipoprotein receptor missense mutations.
Guo J; Gao Y; Li X; He Y; Zheng X; Bi J; Hou L; Sa Y; Zhang M; Yin H; Jiang L
Atherosclerosis; 2019 Feb; 281():1-8. PubMed ID: 30583242
[TBL] [Abstract][Full Text] [Related]
7. A novel low-density lipoprotein receptor variant in a Ukrainian patient: a case report and overview of the disease-causing low-density lipoprotein receptor variants associated to familial hypercholesterolemia.
Moffa S; Onori ME; De Paolis E; Ricciardi Tenore C; Perrucci A; Pontecorvi A; Giaccari A; Urbani A; Minucci A
Mol Biol Rep; 2022 Feb; 49(2):1623-1630. PubMed ID: 34846648
[TBL] [Abstract][Full Text] [Related]
8. Degradation routes of trafficking-defective VLDLR mutants associated with Dysequilibrium syndrome.
Kizhakkedath P; John A; Al-Gazali L; Ali BR
Sci Rep; 2018 Jan; 8(1):1583. PubMed ID: 29371607
[TBL] [Abstract][Full Text] [Related]
9. Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
Grenkowitz T; Kassner U; Wühle-Demuth M; Salewsky B; Rosada A; Zemojtel T; Hopfenmüller W; Isermann B; Borucki K; Heigl F; Laufs U; Wagner S; Kleber ME; Binner P; März W; Steinhagen-Thiessen E; Demuth I
Atherosclerosis; 2016 Oct; 253():88-93. PubMed ID: 27596133
[TBL] [Abstract][Full Text] [Related]
10. Mutation p.L799R in the LDLR, which affects the transmembrane domain of the LDLR, prevents membrane insertion and causes secretion of the mutant LDLR.
Strøm TB; Laerdahl JK; Leren TP
Hum Mol Genet; 2015 Oct; 24(20):5836-44. PubMed ID: 26220972
[TBL] [Abstract][Full Text] [Related]
11. Proteostasis Regulation in the Endoplasmic Reticulum: An Emerging Theme in the Molecular Pathology and Therapeutic Management of Familial Hypercholesterolemia.
Oommen D; Kizhakkedath P; Jawabri AA; Varghese DS; Ali BR
Front Genet; 2020; 11():570355. PubMed ID: 33173538
[TBL] [Abstract][Full Text] [Related]
12. In vitro assessment of the pathogenicity of the LDLR c.2160delC variant in familial hypercholesterolemia.
Lin S; Hu T; Wang K; Wang J; Zhu Y; Chen X
Lipids Health Dis; 2023 Jun; 22(1):77. PubMed ID: 37340302
[TBL] [Abstract][Full Text] [Related]
13. p.(Asp47Asn) and p.(Thr62Met): non deleterious LDL receptor missense variants functionally characterized in vitro.
Benito-Vicente A; Siddiqi H; Uribe KB; Jebari S; Galicia-Garcia U; Larrea-Sebal A; Stef M; Ostolaza H; Palacios L; Martin C
Sci Rep; 2018 Nov; 8(1):16614. PubMed ID: 30413722
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of the p.(Leu15Pro) and p.(Gly20Arg) sequence changes in the signal sequence of LDL receptor.
Pavloušková J; Réblová K; Tichý L; Freiberger T; Fajkusová L
Atherosclerosis; 2016 Jul; 250():9-14. PubMed ID: 27175606
[TBL] [Abstract][Full Text] [Related]
15. Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein B.
Gillian-Daniel DL; Bates PW; Tebon A; Attie AD
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4337-42. PubMed ID: 11904390
[TBL] [Abstract][Full Text] [Related]
16. Compound heterozygous LDLR variant in severely affected familial hypercholesterolemia patient.
Al-Allaf FA; Alashwal A; Abduljaleel Z; Taher MM; Bouazzaoui A; Abalkhail H; Al-Allaf AF; Athar M
Acta Biochim Pol; 2017; 64(1):75-79. PubMed ID: 27878139
[TBL] [Abstract][Full Text] [Related]
17. Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene.
Jiang L; Benito-Vicente A; Tang L; Etxebarria A; Cui W; Uribe KB; Pan XD; Ostolaza H; Yang SW; Zhou YJ; Martin C; Wang LY
Atherosclerosis; 2017 Aug; 263():163-170. PubMed ID: 28645073
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R).
Schaefer JR; Kurt B; Sattler A; Klaus G; Soufi M
Clin Res Cardiol Suppl; 2012 Jun; 7(Suppl 1):2-6. PubMed ID: 22528129
[TBL] [Abstract][Full Text] [Related]
19. AAV vectors expressing LDLR gain-of-function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia.
Somanathan S; Jacobs F; Wang Q; Hanlon AL; Wilson JM; Rader DJ
Circ Res; 2014 Aug; 115(6):591-9. PubMed ID: 25023731
[TBL] [Abstract][Full Text] [Related]
20. Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats.
Etxebarria A; Benito-Vicente A; Stef M; Ostolaza H; Palacios L; Martin C
Atherosclerosis; 2015 Feb; 238(2):304-12. PubMed ID: 25545329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
